뒤로
Salarius Pharmaceuticals, Inc.(SLRX) 가격
SLRX 주가 차트
SLRX 수입
Salarius Pharmaceuticals, Inc.
$0.84
29.23%
$0.18
오늘 기준:Jan 27, 12:47:47 GMT-5
아직 데이터 없음Earnings FAQ
SLRX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Salarius Pharmaceuticals, Inc. SLRX의 지난 분기 매출 실적은 어땠나요?
Salarius Pharmaceuticals, Inc.의 매출 추정치는 얼마인가요?
Salarius Pharmaceuticals, Inc.의 수익 품질 점수는 얼마인가요?
Salarius Pharmaceuticals, Inc.는 언제 수익을 보고하나요?
Salarius Pharmaceuticals, Inc.의 예상 수익은 얼마인가요?
Salarius Pharmaceuticals, Inc.은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.65
시가
$0.706
일일 범위
$0.6865 - $0.8976
52주 범위
$0.5148 - $44.1
거래량
5.9M
평균 거래량
3.6M
EPS(TTM)
-24.24
배당수익률
--
시가총액
$4.9M
Salarius Pharmaceuticals, Inc.란 무엇인가요?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.